TACR1 and glioblastoma: These findings underscore the potent anti‐metastatic and anti‐angiogenic effects of NK‐1R antagonism in glioblastoma and highlight aprepitant as a promising candidate for future in vivo and in ovo therapeutic investigations targeting extracellular matrix (ECM) remodeling, chemotaxis, and angiogenesis.